publicações selecionadas
-
artigo académico
-
artigo de conferência
- Assessing the HPA-axis mediated stress responses in a mouse model of SCA3 2023
- Befiradol treatment ameliorated the motor dysfunction of Spinocerebellar Ataxia Type 3 mouse model 2022
- Chemical screening for novel therapeutic target identification in Machado-Joseph disease 2022
- Pre- clinical study of a 5HT1A specific agonist in the CMVMJD135 mouse model of Machado– Joseph disease 2022
-
documento
- From central to peripheral perspectives in Machado-Joseph Disease: disentangling new therapeutic avenues 2025
- Therapeutic efficacy of chronic 5-HT1A receptor agonism by NLX-112 (befiradol) in Spinocerebellar Ataxia Type 3 mice 2025
- Establishment of a Novel Assay to identify drugs that enhance protein homeostasis: towards treatment of spinocerebellar ataxias 2024
- Therapeutic efficacy of chronic 5-HT1A receptor agonism by NLX-112 (befiradol) in Spinocerebellar Ataxia Type 3 mice 2024
- Therapeutic efficacy of chronic 5-HT1A receptor agonism by NLX-112 (befiradol) in Spinocerebellar Ataxia Type 3 mice" 2024
- Understanding the regulation of stress responses in a mouse model of SCA3 2024
- Unveiling Promising Compounds for Boosting Proteostasis: A Rapid Whole-Animal Organism Phenotypic Assay 2023
- Assessing the HPA-axis mediated stress responses in a mouse model of SCA3 2023
- FastProtAct - FAST-throughput phenotypic assay to identify compounds with PROTeostasis ACTivity. 2023
- Limited Therapeutic Impact of Intermittent Fasting and Ketogenic diets in a Mouse Model of Spinocerebellar Ataxia Type 3 2023
- Identification of novel molecules with proteostasis enhancement activity using a whole-animal based fast-throughput phenotypic assay 2023
- Motor coordination and balance ameliorated after treatment of the CMVMJD135 mouse model of Spinocerebellar Ataxia Type 3 with befiradol 2022
- The study of depression and cognitive comorbidities in a mouse model of spinocerebellar ataxia type 3 2022
- Pre and post-symptomatic treatment with NLX-112 improved the balance and motor coordination of the CMVMJD135 mouse model of Machado-Joseph Disease 2022
- Development of a high-throughput phenotypic assay to screen for chemical enhancers of proteostasis activity in Caenorhabditis elegans 2022
- Befiradol treatment ameliorated the motor dysfunction of Spinocerebellar Ataxia Type 3 mouse model 2022
- Multi-modal analyses converge on the 5-HT1A serotonin receptor and CREB signaling as promising therapeutic targets for SCA3 2022
- Preclinical study of a 5-HT1A receptor specific agonist in the CMVMJD135 mouse model of Machado-Joseph disease 2022
- The study of depression and cognitive comorbidities in a mouse model of spinocerebellar ataxia type 3" 2022
- Understanding the relevance of the cerebellar cognitive affective syndrome in SCA3 mice 2022
- Aripiprazole offsets mutant ATXN3-induced motor dysfunction by targeting dopamine D2 and serotonin 1A and 2A receptors in C. elegans. 2021
- NLX-112 improved the motor coordination and balance in a Mouse Experimental Model of Machado-Joseph Disease 2021
- Suppression of proteotoxic stress by serotonergic signaling 2021
- Does activation of serotonergic treatment suppress proteotoxicity in mouse models of neurodegenerative diseases? 2021
- Targeting of the serotonin (1A) receptor suppresses mutant ataxin-3 pathogenesis in C. elegans. 2019
- Serotonergic signaling activation suppresses proteotoxicity 2019
- NLX-112, a novel 5-HT1A receptor agonist, suppresses pathogenesis of mutant ATXN3 in C. elegans 2019
- NLX-112, a novel 5-HT1A receptor agonist, supresses neuronal dysfunction in a C. elegans model of Spinocerebellar Ataxia 2019
- Targeting of the Serotonin (1A) Receptor Suppresses Mutant Ataxin-3 Pathogenesis in C. elegans 2019
- Efficacy of chronic 5-HT 1A receptor agonism by NLX-112 in a mouse model of Spinocerebellar Ataxia type 3
- The 5-HT 1A receptor agonist NLX-112 rescues motor swimming deficits in Spinocerebellar Ataxia type 3 mice